Welcome to our dedicated page for Acura Pharm SEC filings (Ticker: ACUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
acura pharmaceuticals, inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. we have discovered and developed three proprietary technology platforms to address abuse and misuse across multiple fronts. • limitx™ technology is designed to retard the release of active drug ingredients when an excess number of tablets are ingested. in 2014, we were awarded a $300,000 grant from the national institute on drug abuse to advance early stage development of our limitx technology. • aversion® technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features to discourage common methods of pharmaceutical product misuse and abuse while providing effective pain relief. oxaydo® tablets (oxycodone hcl, cii), is the first approved product using aversion® in the united states. on january 7, 2015, we entered intAcura Pharmaceuticals, Inc. received three new
Acura Pharmaceuticals director Immanuel Thangaraj reported equity compensation activity involving restricted stock units (RSUs) and common stock. On January 2, 2026, 50,000 RSUs previously granted on January 2, 2025 were exchanged on a one-for-one basis into 50,000 shares of common stock, with par value of $0.01 per share paid on exchange. On the same date, he received a new grant of 50,000 RSUs under the 2021 plan, which vest 25% on the last day of each of March, June, September and December 2026, with provisions for immediate vesting upon a change of control and certain other events, and an election to take up to 40% in cash instead of shares. After these transactions, he directly holds 547,647 shares of common stock and 50,000 RSUs, and there are an additional 1,956,396 shares reported as indirectly owned by Essex Woodlands Health Ventures Fund V, L.P., where he is a managing director of the general partner and disclaims beneficial ownership except to the extent of his pecuniary interest.
Acura Pharmaceuticals director William G. Skelly reported equity compensation activity involving restricted stock units and common shares. On January 2, 2026, 50,000 restricted stock units granted on January 2, 2025 were exchanged on a one-for-one basis into 50,000 shares of common stock, with par value of $0.01 per share paid upon exchange. On the same date, Skelly received a new grant of 50,000 restricted stock units under the 2021 plan, which vest 25% on the last day of each of March, June, September and December 2026, with immediate vesting upon a change of control and certain other events. Following these transactions, Skelly beneficially owned 675,989 shares of common stock and 50,000 restricted stock units, all held directly.
Acura Pharmaceuticals director George K. Ross reported equity compensation activity involving restricted stock units (RSUs) and common stock. On January 2, 2026, he acquired 50,000 shares of common stock through an RSU exchange under the 2021 plan, bringing his directly held common stock to 595,903 shares following the transaction.
The filing also shows derivative activity in RSUs. A block of 50,000 RSUs previously granted on January 2, 2025 was exchanged on a one-for-one basis into common stock upon payment of par value of $0.01 per share. In addition, Ross was granted a new award of 50,000 RSUs on January 2, 2026, vesting 25% on the last day of each of March, June, September, and December 2026, with provisions for immediate vesting upon a change of control and certain other events and an election to take up to 40% of the RSUs in cash.
FAQ
What is the current stock price of Acura Pharm (ACUR)?
What is the market cap of Acura Pharm (ACUR)?
